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SUMMARY
Neuronal activity-regulated gene expression has been suggested to be an important mediator of the
ability of experience to effect long-lasting changes in the structure and function of the nervous
system, but the activity-dependent component of gene transcription has never been selectively
isolated and tested for its biological significance in the nervous system. Here we describe the
generation of an animal that is specifically impaired in the neuronal activity-dependent
transcription of the Bdnf gene. The introduction of a subtle knock-in mutation into the mouse Bdnf
gene that blocks the ability of the activity-regulated factor CREB to bind Bdnf promoter IV results
in an animal in which the sensory experience-dependent induction of Bdnf expression is disrupted
in the cortex. Neurons from these animals form fewer inhibitory synapses in culture, have fewer
spontaneous inhibitory quantal events in acute cortical slices, and exhibit reduced immunostaining
for inhibitory presynaptic markers in the cortex. These results indicate a specific requirement for
activity-dependent Bdnf expression in the development of inhibition in the cortex and demonstrate
that the activation of gene expression in response to experience-driven neuronal activity has
important biological consequences for the development and function of the nervous system.
INTRODUCTION
Experience-dependent changes in the nervous system occur throughout the lifetime of an
animal. Sensory experience mediates the structural and functional refinement of developing
neuronal circuits (Fox and Wong, 2005), and, in the mature brain, use-dependent
modification of neuronal circuits underlies important adaptive functions of the nervous
system, including learning, memory, and behavior (Kandel, 2001). The discovery that
excitatory neurotransmitters can stimulate new gene transcription by triggering an influx of
calcium into post-synaptic neurons (Greenberg et al., 1986; Kornhauser et al., 1990; Morgan
et al., 1987) suggested a compelling mechanism by which stimulus-evoked neuronal activity
might effect long-lasting changes in the structure and function of the nervous system. In the
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two decades since, significant advances have been made in elucidating many of the key
activity-responsive transcriptional regulators, the calcium-dependent signaling pathways that
couple extracellular stimuli to their activation, and the programs of gene expression that are
activated in response to neuronal activity (Lanahan and Worley, 1998; West et al., 2002).
Activity-dependent gene expression occurs when synaptic activation triggers calcium influx
at the membrane through ligand- and voltage-gated calcium channels, thereby initiating
calcium-dependent signaling cascades that amplify and carry the signal to activate
transcription factors in the nucleus. Several searches for activity-regulated genes have
identified approximately 300 genes as being responsive to neuronal activity (Bartel et al.,
1989; Lanahan and Worley, 1998; Lin et al., 2008; Nedivi et al., 1993), many of which fall
into one of two categories. The first category includes genes that themselves encode for
transcriptional regulators, exemplified by the classic immediate early gene c-fos (Greenberg
et al., 1986) or the neuronal bHLH/PAS factor npas4 (Lin et al., 2008). The second category
includes genes that encode for neuronally enriched proteins that are believed to function
directly at the synapse and play important roles in neural development and plasticity, such as
Bdnf (Poo, 2001).
There is no doubt that genes whose transcription is regulated by activity are important for
the development and function of the brain. However, despite considerable progress in our
understanding of the program of neuronal activity-regulated gene expression, direct
evidence that the activity-dependent component of transcription per se is specifically
important for nervous system development or function has been elusive. This fact is due in
part to limitations in our ability to experimentally manipulate the activity-dependent
component of transcription independent of the many other genetic programs regulating a
given gene’s transcription. For instance, the role of an activity-regulated gene is most often
investigated through loss-of-function studies that remove the gene entirely, independent of
the stimulus state or cellular context. This approach can often lead to an outcome in which
the functions of a gene that are dependent on its activity-dependent expression are conflated
with, for instance, its trophic functions in supporting cell health or survival. In the case of
one of the best-studied activity-regulated genes, brain-derived neurotrophic factor (Bdnf),
studies in mice that completely lack Bdnf have demonstrated that it plays a key role in
neuronal survival, differentiation, migration, and dendritic arborization (Ernfors et al., 1994;
Jones et al., 1994; Schwartz et al., 1997). In addition, mice heterozygous for the loss of a
Bdnf allele show deficits in synaptic development, function, and plasticity, as well as
changes in body weight regulation, locomotor activity, and aggression (Abidin et al., 2008;
Abidin et al., 2006; Carter et al., 2002; Kernie et al., 2000; Korte et al., 1995; Lyons et al.,
1999; Patterson et al., 1996). Many of these diverse functions of Bdnf, in particular its
functions in synaptic development, function, and plasticity, are thought to be regulated at
least in part by its neuronal activity-dependent expression (Poo, 2001), but direct evidence
for this idea is lacking.
In support of the idea that the many functions of Bdnf in the nervous system may be
dependent on the tight temporal, spatial, and stimulus-specific regulation of Bdnf expression
is the complexity of its gene structure. The Bdnf gene is comprised of at least eight distinct
promoters that initiate transcription of multiple distinct mRNA transcripts, each of which
contains an alternative 5’ exon spliced to a common 3’ coding exon that contains the entire
open reading frame for the BDNF protein (Aid et al., 2007). Through the use of alternative
promoters, splice donors, and polyadenylation sites, at least 18 distinct transcripts can be
produced from the Bdnf gene (Figure 1A); remarkably, however, each of these Bdnf mRNAs
encodes an identical BDNF protein. The functional significance of the transcriptional
organization of the Bdnf gene remains cryptic, but one attractive hypothesis is that the
production of many mRNAs that all encode the same protein product provides for multiple
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layers of regulation of BDNF expression, for instance, at the level of alternative promoter
usage, differential mRNA stability and translatability, or differential subcellular localization
of either the mRNA message(s) or protein. In support of this idea, it is well known that the
various Bdnf promoters are differentially responsive to neuronal activity; in particular, in the
cortex, promoter IV-dependent Bdnf transcription accounts for the majority of neuronal
activity-induced Bdnf expression (Tao et al., 1998; Timmusk et al., 1994; Timmusk et al.,
1993). This observation prompted us to ask whether we could take advantage of our
understanding of the activity-dependent regulation of the Bdnf gene to generate an animal
model that allows us to ask which, if any, of the physiological functions of Bdnf in the
nervous system are specifically controlled by the neuronal activity-regulated component of
its expression.
Our lab and others have extensively investigated the activity-dependent activation of Bdnf
promoter IV as a model for understanding the mechanisms mediating calcium-induced
neuronal gene expression. Experiments using a plasmid-based reporter to recapitulate
promoter IV activity revealed that a cAMP/Ca++-response element-like element (CaRE3/
CRE) proximal to the exon IV transcription start site is important for the ability of
membrane depolarization to induce promoter IV activation (Shieh et al., 1998; Tao et al.,
1998). In vitro studies indicate that this element is bound by the transcription factor CREB, a
calcium-regulated factor that has important functions in controlling many adaptive neuronal
responses. CREB bound at promoter IV becomes phosphorylated by calcium-regulated
kinase cascades in response to neuronal activity and subsequently recruits components of the
basal transcriptional machinery to Bdnf promoter IV to activate gene expression (Lonze and
Ginty, 2002; West et al., 2001).
Here we report that mutation of the CaRE3/CRE (CREm) at endogenous Bdnf promoter IV
by gene targeting results in an animal in which the neuronal activity-dependent component
of Bdnf transcription in the cortex is specifically disrupted. CREm knock-in mice exhibit a
reduction in the number of inhibitory synapses formed by cortical neurons in culture, a
reduction in spontaneous inhibitory quantal transmission measured in acute brain slices, and
a reduction in the level of inhibitory presynaptic markers in the cortex. These findings
provide a clear demonstration of a biological role for activity-dependent gene expression in
the regulation of cortical inhibition, and also indicate a requirement for promoter IV-derived
Bdnf expression in this process. Interestingly, our findings point to a previously
unappreciated role for CREB in regulating inhibitory synapse development and demonstrate
the utility of mice bearing subtle mutations in gene regulatory regions for uncovering novel,
target-specific functions for a transcription factor that may not be revealed by traditional
loss-of-function studies.
RESULTS
Generation of a mouse model with impaired activity-dependent Bdnf expression
We chose to focus on the Bdnf gene as a model for understanding the functional significance
of neuronal activity-regulated gene expression in the brain for several reasons. First, a large
body of work has demonstrated a critical role for Bdnf in many diverse processes in nervous
system development and function (Poo, 2001), many of which are regulated by neuronal
activity. Second, perhaps more than any other activity-regulated gene, the mechanisms by
which calcium influx induces Bdnf transcription have been extensively studied, lending
insight into the type of genetic lesion that could potentially block activity-dependent
expression of the gene (West et al., 2001). In the cortex, for example, promoter IV-derived
Bdnf transcripts comprise the majority of neuronal activity-induced Bdnf expression (Tao et
al., 1998; Timmusk et al., 1994; Timmusk et al., 1993). In addition, unlike many other
prototypical immediate early genes such as c-fos, the induction of Bdnf exon IV-containing
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transcripts is selectively activated by the influx of extracellular calcium through ligand- and
voltage-gated calcium channels; growth factor stimulation, for instance, does not induce
robust promoter IV activation. Thus, we reasoned that disruption of exon IV-containing
Bdnf transcripts might be sufficient to specifically attenuate activity-dependent expression of
Bdnf in the cortex.
Previous studies investigating the mechanisms of Bdnf promoter IV activation have
demonstrated that an evolutionarily conserved 170-bp fragment proximal to the exon IV
transcriptional start site is sufficient to confer Ca2+-selective responsiveness to a plasmid-
based reporter gene when transfected into neurons in vitro. Mutagenesis analysis revealed
the existence of three Ca2+-responsive elements (CaREs), CaRE1, CaRE2, and CaRE3/CRE
(Figure 1C), each of which, when individually mutated, was sufficient to attenuate activity-
dependent induction of the promoter IV reporter (Tao et al., 1998). At the time we began
this study, the prevailing view was that CaRE1 is bound by the calcium-responsive
transcription factor, CaRF (Tao et al., 2002); CaRE2 contains an E-box element and is
bound by the bHLH transcription factors, USF1 and USF2 (Chen et al., 2003b); and CaRE3
is a cAMP/Ca++-response element (CRE)-like element that is bound by CREB (Tao et al.,
1998).
Based on the available information at the time, we used homologous recombination in
embryonic stem cells to generate three independent lines of mutant mice in which
endogenous Bdnf promoter IV is genetically disrupted (Figure 1B). First, we generated a
deletion in Bdnf promoter IV (pIV−/−) that removes the previously mapped 170-bp proximal
promoter fragment, as well as the transcriptional start site, to completely abrogate
transcription from promoter IV. Second, we introduced point mutations into the CREB-
binding site CaRE3/CRE element of Bdnf promoter IV (CREmKI, Figure 1B, 1D), which
was predicted to block promoter IV induction based on the plasmid reporter assay. Finally,
since it is unknown whether mutation of an individual transcriptional control element can
independently affect promoter activity in the context of endogenous chromatin, we also
generated a third line in which we introduced point mutations into each of the CaRE1,
CaRE2, and CaRE3/CRE elements of Bdnf promoter IV in combination (triple-site mutant,
TMKI, Figure 1B, 1D). We reasoned that a combination of mutations might function more
effectively to block promoter IV activation than mutation of the CaRE3/CRE alone, since
previous studies at the c-fos promoter suggest that the concerted action of multiple
transcriptional elements is required for gene regulation (Robertson et al., 1995).
For each mutant line, the gene targeting strategy to introduce the mutation into Bdnf
promoter IV in embryonic stem cells necessitates the introduction of a 34-bp loxP sequence
in the vicinity of the mutation as a by-product of the selection procedure after homologous
recombination. To control for the possibility that the presence of the loxP sequence could
affect gene expression from the Bdnf locus in unexpected ways, we generated a fourth
mouse line in which promoter IV is left unaltered but that differs from a wildtype mouse
only by the presence of the loxP sequence in an unconserved region of the large intron
between exons VII and VIII (loxP control). Since the loxP site in all three mutants, pIV−/−,
CREmKI, and TMKI, is engineered into this identical location (Figure 1B), any differences
seen in the mutant lines as compared to the loxP control must therefore stem from their
respective mutations at Bdnf promoter IV. Southern blot analysis of genomic DNA isolated
from the targeted ES cells, as well as from heterozygous and homozygous mutant mice for
all four mutant mouse lines, pIV−/, CREmKI, TMKI, and loxP control, resulted in the
predicted mutant allele structure after recombination (Figure 1C, Supplemental Figure 1,
data not shown). The CREmKI, TMKI, and loxP control mutations were further verified by
direct sequencing of the genomic DNA from homozygous mutants (Figure 1D).
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Mutation of the CREB-binding site in Bdnf promoter IV impairs neuronal activity-regulated
Bdnf transcription
To test whether the introduction of pIV−/−, CREmKI, and TMKI mutations into Bdnf
promoter IV blocks neuronal activity-dependent Bdnf expression, we prepared dissociated
primary cortical cultures from the brains of homozygous mutant and wildtype or loxP
control littermates for each mutant line. Following maintenance in vitro for 5 days (5DIV),
neurons were depolarized with high extracellular potassium chloride for varying amounts of
time, RNA was extracted, and the levels of Bdnf mRNA transcripts were measured by
quantitative real-time PCR (qPCR). As expected, deletion of Bdnf promoter IV results in a
complete loss of exon IV-containing Bdnf mRNAs (Figure 2A). Furthermore, mutation of
either all three CaREs in combination or of the CaRE3/CRE alone is sufficient to cause an
approximately 90% reduction in the level of Bdnf promoter IV induction (Figure 2B, 2C).
This failure of Bdnf promoter IV activation does not reflect a general defect in calcium-
dependent signaling in these mutants because the induction of other immediate early genes,
including c-fos, activity-regulated cytoskeletal-associated protein (Arc), and the other major
activity-regulated Bdnf transcript exon I, is unaffected in pIV−/−, CREmKI, or TMKI
neurons (Figure 2G–I; Supplemental Figure 2; and data not shown). The impairments in
promoter IV activation result in an approximately 70% or 60% reduction in the activity-
dependent induction of total Bdnf mRNA in pIV−/− or CREmKI and TMKI cortical neurons,
respectively (Figure 2D–F). This impairment in total Bdnf mRNA induction is reflected in
an approximately 50% decrease in BDNF protein levels in pIV−/− or CREmKI cortex
(Supplemental Figure 3, see also Figure 4F). Thus, all three mutations are sufficient to cause
a significant impairment in activity-dependent Bdnf expression in neurons.
We chose to focus our study on the CREmKI mutant for several reasons. First, the CREmKI
mutation represents a subtle change in nucleotide sequence, but is sufficient to cause a
substantial impairment in the activity-dependent induction of Bdnf, comparable to that
observed in TMKI neurons. Second, the CREmKI mutant provides several significant
advantages over the pIV−/− mutant for selectively evaluating the functional significance of
both activity-dependent and promoter IV-dependent Bdnf transcription. Whereas the pIV−/−
deletion mutant completely removes promoter IV-derived transcript independent of the
stimulus state of the neurons, the CREmKI mutant impairs Bdnf promoter IV activation
specifically in response to neuronal activity-dependent rises in calcium by eliminating
binding of the Ca2+-regulated factor CREB to Bdnf promoter IV (see below, Figure 8). The
CREmKI mutation has an additional advantage in that it maintains the endogenous
configuration of the Bdnf locus, thereby circumventing potential artifacts that can arise in
deletion mutants where the spacing among residual promoter elements and exons is
changed. Finally, since previous studies strongly suggest that the CaRE3/CRE element in
Bdnf promoter IV is bound by CREB (Tao et al., 1998), the CREmKI mutant also has the
potential to provide insight into specific functions of CREB-dependent gene regulation in
the nervous system.
CREmKI mice are viable, fertile, born in the expected Mendelian ratios, and visually
indistinguishable from loxP control littermates. In addition, CREmKI animals have
comparably sized brains to loxP control animals, show no gross anatomical alterations in
cortical, cerebellar, or hippocampal structure, no obvious changes in gait, and no obvious
defects in cortical layering (see Methods, Supplemental Figure 4, and data not shown).
These observations suggest that, in contrast to the complete loss of Bdnf in Bdnf−/− mutants,
the introduction of a subtle knock-in mutation into Bdnf promoter IV to specifically impair
activity-dependent Bdnf expression does not have a strong effect on neuronal survival.
To investigate how the CREmKI mutation affects activity-regulated Bdnf expression in
response to glutamate receptor activation, we treated 12 DIV cortical neurons, which have
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developed many more synaptic contacts than 5DIV neurons, with NMDA to stimulate
NMDA-type glutamate receptors, a major mediator of excitatory neurotransmission. Similar
to our findings under membrane-depolarizing conditions, we observed significant
impairments in the activation of Bdnf promoter IV and total Bdnf expression in CREmKI
neurons as compared to loxP control neurons (Figure 3A and 3B) in response to NMDA
stimulation. Interestingly, when we examined the expression of the remaining major Bdnf
transcripts (Figure 1A) as well as other activity-regulated genes in 12 DIV CREmKI
neurons, we were surprised to find that the induction of most immediate-early genes,
including neuronal pentraxin 2 (NP2), Arc, c-fos, as well as Bdnf exons I and II, is
significantly upregulated in response to stimulation with NMDA (Figure 3C–F and data not
shown). These observations raise the interesting possibility that the general increase in
neuronal activity-dependent transcription in 12 DIV CREmKI neurons may be secondary to
an increase in their overall level of excitability. These differences may not be obvious after
only five days in culture when neurons are not extensively synaptically connected (Figure
2G–I).
Mutation of the CREB-binding site in Bdnf promoter IV impairs sensory experience-driven
Bdnf transcription in the intact brain
We next examined whether the activity-dependent expression of Bdnf in the intact CREmKI
brain is affected in response to a physiologically relevant environmental stimulus. Adult
mice were maintained in total darkness for fourteen days to reduce levels of sensory
activity-driven transcripts in the visual cortex. RNA was then harvested from the primary
visual cortex of mice that were either maintained in darkness or exposed to light for 90
minutes, and the levels of Bdnf transcripts were measured by qPCR. We found that the
nearly 20-fold increase in the levels of exon IV-containing transcripts measured in loxP
control visual cortex in response to light exposure is reduced by approximately 75% in
CREmKI visual cortex (Figure 4A). The activity-dependent induction of gene expression
measured in the visual cortex is specific to visual experience because it is not observed in
the somatosensory cortex of either loxP control or CREmKI brains (Supplemental Figure 5).
Interestingly, we also observed that many other immediate-early genes, including c-fos, Arc,
and NP2, are more highly induced in the visual cortex of CREmKI animals in response to
light stimulation when compared to loxP controls (Figure 4B and data not shown).
Moreover, measurements of activity-dependent gene expression in the cortex of CREmKI
and loxP control animals given seizures by administration of the chemoconvulsant kainic
acid resulted in similar findings (Figure 4C–E and Supplemental Figure 6). The heightened
induction of many activity-regulated genes in response to neuronal activity in CREmKI
animals compared to controls again suggests the possibility of changes in the excitability of
neuronal circuits in the CREmKI brain.
The impairment in activity-dependent Bdnf promoter IV transcription in response to light
exposure in CREmKI visual cortex results in an approximately 50% decrease in the
induction of total Bdnf transcripts driven by sensory stimulation (Figure 4A), as compared to
loxP control animals. This reduction in Bdnf mRNA is reflected in an approximately 60%
decrease in the induction of BDNF protein levels in visual cortex in response to visual
experience (Figure 4F). Importantly, the CREmKI mutation does not appear to affect Bdnf
expression under conditions of significantly reduced neuronal activity, since levels of both
promoter IV-derived and total Bdnf transcripts are similar in sensory-deprived loxP control
and CREmKI visual cortex (Figure 4G, P>0.05). Taken together, these results provide
strong evidence that the neuronal activity-dependent component, but not the basal
component, of Bdnf transcription is selectively impaired in the intact brains of CREmKI
animals in response to a physiologically relevant sensory experience and demonstrate the
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utility of the CREmKI animal model for examining the functional significance of neuronal
activity-regulated gene expression for nervous system development and function.
Neuronal activity-dependent Bdnf expression regulates the development of inhibition in
the nervous system
Our observations that the neuronal activity-dependent induction of many immediate early
genes, including non-promoter IV-derived Bdnf transcripts, c-fos, NP2, or Arc, is enhanced
in mature CREmKI neuronal cultures or in the intact brain of CREmKI mutants suggested
that neuronal connectivity may be altered in CREmKI brains. In addition, a large body of
work has independently established both BDNF and neuronal activity as positive regulators
of inhibitory synapse development. For example, application of recombinant BDNF or
BDNF overexpression promotes the development of inhibition (Huang et al., 1999; Ohba et
al., 2005), whereas reduction of neuronal activity using pharmacological blockers or by
sensory deprivation retards the maturation of inhibition (Benevento et al., 1995; Hendry and
Jones, 1986; Rutherford et al., 1997). A compelling hypothesis that arises from this work
suggests that neuronal activity regulates the development of inhibitory synapses through its
effects on Bdnf gene transcription. The CREmKI mutant allows us to directly test this
hypothesis by asking whether the impairment in activity-dependent Bdnf expression affects
the development of inhibition in the nervous system.
To specifically investigate the effect of the CREmKI mutation on the development of
inhibitory synapses, we first prepared low-density cortical cultures from CREmKI and loxP
control littermates that allowed us to quantify synapse density by immunostaining. Neurons
were transfected with a plasmid encoding green fluorescent protein (GFP) at 5DIV, and
fixed and immunostained at 18 DIV with antibodies that recognize the presynaptic
inhibitory marker GAD65 and the postsynaptic inhibitory marker GABAA receptor γ2
subunit (GABAARγ2). The number of inhibitory synapses that form on a neuron was
quantified as the number of co-localized GAD65 and GABAARγ2 puncta that overlap with
GFP signal (Figure 5A, 5B).
Using these criteria, we observed that significantly fewer inhibitory synapses form on
CREmKI cortical neurons than on loxP control littermate neurons in culture (Figure 5A–C).
A similar result was also seen when inhibitory synapses were quantified using an
independent set of markers, the inhibitory presynaptic marker VGAT and the inhibitory
postsynaptic marker GABAA receptor β2/3 subunits (Figure 5D). The decrease in synapse
number in CREmKI neurons appears specific to inhibitory synapses because no difference
in the number of excitatory synapses was detected when CREmKI neurons were compared
to loxP control neurons using the presynatic marker synapsin I and the excitatory
postsynaptic marker PSD95 (Figure 5E). In addition, the reduction in inhibitory synapse
number in CREmKI neurons does not appear to be secondary to poor cell health since no
significant differences between CREmKI and loxP control littermate neuronal cultures were
observed in the number of pyknotic nuclei present (data not shown) or in the extent of
dendritic arborization, as quantified by Sholl analysis (Figure 5F). These results demonstrate
that the activity-dependent expression of Bdnf is important for the development of
inhibitory, but not excitatory, synapses in neurons maintained in culture.
Although many of the key steps of synaptogenesis are recapitulated by dissociated neurons
as they re-establish their connections in culture (Ziv and Garner, 2004), we also wanted to
examine the role of activity-dependent Bdnf expression in regulating the development of
inhibition in the context of an endogenous neural circuit. Since our previous data indicate
that visual experience-dependent Bdnf transcription is impaired in CREmKI brains, and
because previous studies have implicated Bdnf in the regulation of cortical inhibition and
plasticity in the visual cortex, we chose to measure the number of functional inhibitory
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synapses that form on neurons in an intact circuit in the primary visual cortex of CREmKI
animals. We prepared acute slices containing primary visual cortex (V1) from the brains of
P16-P18 CREmKI or loxP control littermates and obtained whole-cell patch clamp
recordings from layer II/III pyramidal neurons in V1 to measure spontaneous miniature
inhibitory postsynaptic currents (mIPSCs) (Figure 6A). Pharmacologically isolated mIPSCs
were demonstrated to be GABAAR-mediated, since they were abolished by treatment with
picrotoxin (data not shown). We observed a significant decrease in the frequency of mIPSC
events in CREmKI neurons (interevent interval, 742.4±36.8 vs. 355.4±14.7 ms, CREmKI
and loxP control, respectively; Figure 6B–C(i)), suggesting that impaired activity-dependent
Bdnf transcription in CREmKI cortex results in fewer functional inhibitory synapses as
compared to loxP control. Interestingly, we also found a significant increase in the
amplitude of mIPSCs in CREmKI neurons (28.1±0.7 vs. 23.9±0.7 pA, CREmKI and loxP
control, respectively; Figure 6B–C(ii)), suggesting that activity-dependent Bdnf expression
can regulate inhibitory synapse strength. Whereas the change in mIPSC amplitude in
CREmKI neurons might reflect the direct action of activity-dependent Bdnf on vesicle
neurotransmitter content or postsynaptic GABAA receptor number, it could also occur
secondarily as a homeostatic adjustment to the decrease in inhibitory input number.
Nevertheless, these findings are consistent with our measurements by immunofluorescence
staining in cultured cortical neurons indicating that fewer inhibitory synapses form on
CREmKI neurons and strongly support the hypothesis that activity-dependent Bdnf
transcription plays a critical role in GABAergic synapse development in the nervous system.
Because mIPSCs reflect the spontaneous release of individual neurotransmitter vesicles at
presynaptic sites of contact, changes in mIPSC frequency correlate with changes in
inhibitory synapse number, but they can also be affected by changes in presynaptic
properties such as the probability of neurotransmitter vesicle release. As an independent
measurement of inhibitory synapse number in CREmKI neurons connected together in an
endogenous circuit, we immunostained histological sections of visual cortex prepared from
P20-P24 CREmKI or loxP control littermates for inhibitory synaptic markers. We observed
modest, but significant decreases in the intensity of staining for the inhibitory presynaptic
markers GAD65 and VGAT in layer II/III of CREmKI visual cortex as compared to loxP
control visual cortex (Figure 7A–C), consistent with a reduction in inhibitory synapse
number in CREmKI neurons. However, immunostaining for the presynaptic marker
synapsin I (data not shown) or the excitatory presynaptic marker VGLUT1 (Figure 7A, 7D)
is similar in CREmKI and loxP control visual cortex, consistent with our previous
observation that excitatory synapse development is unaffected in CREmKI neurons in
culture. Taken together, our data demonstrate a role for neuronal activity-dependent Bdnf
expression in the development of inhibition in the cortex, and suggest that impairments in
activity-dependent Bdnf transcription lead to a shift in the ratio of excitation to inhibition in
the brain that may increase the excitability of the CREmKI brain.
To begin to gain insight into the cellular mechanisms by which activity-dependent Bdnf
expression regulates inhibitory synapse number, we next asked whether the decrease in
inhibition observed in CREmKI brains might be a simple consequence of changes in the
number of cortical inhibitory neurons, since total Bdnf null mice exhibit a dramatic
reduction in the density of parvalbumin-positive and NPY-positive inhibitory neurons in the
cortex (Jones et al., 1994). We focused our analysis on these populations of interneurons and
employed stereological methods to quantify the number of parvalbumin-or NPY-positive
neurons in the visual cortex of CREmKI or loxP littermate control mice. To control for any
possible changes in cell density, interneuron counts were normalized to the total number of
cell nuclei as quantified by the DNA-binding dye Hoechst 33342. We observed no
significant difference in the number of either parvalbumin- or NPY-positive interneurons in
CREmKI visual cortex (Figure 7E, 7F), suggesting that reductions in inhibitory synapse
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number in CREmKI neurons are not secondary to changes in inhibitory neuron number.
Since no molecular marker exists that can easily label all known GABAergic cell types, we
cannot exclude the possibility that the differentiation of other classes of interneurons is
affected in CREmKI mutants. However, since parvalbumin- and NPY-positive interneurons
together comprise more than 50% of the inhibitory neurons in the cortex, and since these
specific populations of interneurons have been previously shown to be Bdnf-dependent in
the context of the complete loss of Bdnf, our data suggest that the activity-dependent
component of Bdnf expression is important for the formation or maintenance of inhibitory
synapses by GABAergic neurons, but not for the survival or differentiation of GABAergic
neurons.
Loss of CREB binding leads to disassembly of the transcriptional activating complex at
Bdnf promoter IV
As the loss of activity-dependent Bdnf expression in CREmKI animals is due to the specific
mutation of the CaRE3/CRE in Bdnf promoter IV, a sequence that is bound by the
transcription factor CREB, our results also potentially point to a role for CREB in inhibitory
synapse development that has not been previously described. CREB is a well-established
regulator of calcium-dependent gene expression that has important functions in nervous
system development and function, including survival, synaptic plasticity, and learning and
memory (Flavell and Greenberg, 2008; West et al., 2002). The central role of CREB in
neuronal survival and maintenance has hampered the study of CREB function in mature
neurons; for instance, postnatal disruption of CREB in the forebrain leads to widespread
neurodegeneration (Mantamadiotis et al., 2002), preventing the study of other CREB
functions in these neurons. However, given that CREB regulates a transcriptional program
comprising hundreds, if not thousands of genes (Impey et al., 2004), only a portion of which
are involved in survival, many additional functions of CREB in the nervous system
undoubtedly remain to be discovered. Our findings with CREmKI mice suggest that one of
these additional functions of CREB is the control of inhibitory synapse development via the
calcium-dependent regulation of Bdnf expression.
To explore this idea, we used chromatin immunoprecipitation (ChIP) to directly assess the
effect of the CREmKI mutation on the binding of CREB to endogenous Bdnf promoter IV in
the brain. Forebrains from CREmKI and loxP littermate control mice were treated with
formaldehyde to covalently crosslink endogenous protein-DNA complexes, which were then
mechanically sheared and immunoprecipitated with an antibody against CREB. The
specificity of the anti-CREB antibody for use in ChIP experiments has been previously
validated in neurons that lack CREB protein (Riccio et al., 2006). qPCR measurements
indicated that whereas Bdnf promoter IV-containing DNA fragments are enriched in CREB
immunoprecipitates prepared from loxP control brains as compared to control
immunoprecipitates from loxP control brains, CREB immunoprecipitates from littermate
CREmKI brains do not contain detectable levels of Bdnf promoter IV gDNA (Figure 8B).
The failure to detect CREB binding at promoter IV in CREmKI brains is not due to
differences in the level of CREB expression (Figure 8A) or the ability to immunoprecipitate
CREB under crosslinking conditions between CREmKI and loxP control brains (Figure 8A),
and we detected robust CREB binding to other known CRE-containing CREB target
promoters, such as c-fos or Nr4a1, in CREmKI brains (Figure 8B and data not shown). In
contrast, we detected no binding of CREB in either loxP control or CREmKI brains to
negative control regions in Bdnf intron VII, in the Bdnf 3’ untranslated region (UTR), or
within the Nr4a1 gene (Figure 8B and data not shown). Taken together, these data provide
the first direct demonstration that Bdnf promoter IV is an endogenous target gene of CREB
in the brain and demonstrate that mutation of the promoter IV CaRE3/CRE element
abrogates CREB binding to Bdnf promoter IV in the intact brain. Together with our earlier
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experiments demonstrating that Bdnf promoter IV transcription is induced upon activity-
dependent CREB phosphorylation (Tao et al., 1998), these findings strongly suggest that the
impairment in neuronal-activity dependent induction of Bdnf expression in CREmKI mice is
due to a loss of CREB-binding and regulation at promoter IV.
Since our initial characterization of CaRF (Tao et al., 2002), USF1/2 (Chen et al., 2003b),
and CREB (Tao et al., 1998) as important regulators of Bdnf promoter IV activation,
ongoing work in our lab and others has described additional components of the
transcriptional regulatory complex at promoter IV, including the transcription factors
BHLHB2 (Jiang et al., 2008), NPAS4 (Lin et al., 2008), and MEF2 (S.W.F., T.K.K., and
M.E.G., manuscript in preparation); the methyl-DNA binding protein MeCP2 (Chen et al.,
2003a; Martinowich et al., 2003); and the transcriptional co-activator CBP (West et al.,
2001). These factors are believed to function together with CREB to confer calcium-and
neural cell type-specific regulation of Bdnf transcription, but little is understood about how
they cooperate with one another to regulate transcription or how they affect the recruitment
of one another to Bdnf promoter IV. We took advantage of the CREmKI mutant to assess the
contribution of CREB to the assembly of various components of the transcriptional
activating complex at Bdnf promoter IV.
We first examined whether loss of CREB binding affects the recruitment of the
transcriptional co-activator CBP to Bdnf promoter IV. Phosphorylation of CREB at Ser133
in response to rises in intracellular calcium recruits the binding of CBP, which functions as a
transcriptional co-activator both through its intrinsic histone acetyltransferase activity and
through its stabilization of components of the pre-initiation complex at promoters (Hong et
al., 2005; Lonze and Ginty, 2002). Although CBP has been best studied in the context of co-
regulation with CREB, it is a general transcriptional co-factor that cooperates with a wide
variety of other transcription factors, including MEF2 (Sartorelli et al., 1997). Performing
ChIP with an antibody directed against CBP, we observed significant binding of CBP to
Bdnf promoter IV in loxP control brains that was almost completely absent in CREmKI
littermate brains (Figure 8C). By contrast, in both CREmKI and loxP control brains, we
detected strong binding of CBP to the c-fos promoter and relatively little binding of CBP in
the Bdnf 3’ UTR negative control region (Figure 8C). These data indicate that loss of CREB
binding to Bdnf promoter IV disrupts the binding of the general transcriptional co-activator
CBP to the promoter as well. To determine how loss of CBP binding to Bdnf promoter IV
affects the recruitment of the basal transcriptional machinery, we also performed ChIP with
an antibody (monoclonal 8WG16) directed against the hypophosphorylated state of the
largest subunit of RNA polymerase II, which is specifically enriched at transcriptional start
sites (Brodsky et al., 2005). In the absence of CREB binding to promoter IV in CREmKI
brains, we also observed a significant reduction in the level of Pol II docked at the promoter
(Figure 8D), consistent with the impairment in activity-dependent transcription from Bdnf
promoter IV (Figure 2C, Figure 3A, Figure 4A). Pol II binding at the c-fos promoter was not
affected in CREmKI brains (Figure 8D), indicating that the loss of polymerase binding in
CREmKI brains is specific to promoter IV. Together, these results indicate that the loss of
binding of a single sequence-specific factor, CREB, to Bdnf promoter IV is sufficient to
disrupt the assembly of the general transcriptional activation machinery used by many
transcription factors at Bdnf promoter IV.
Finally, we asked whether loss of CREB binding to Bdnf promoter IV affects the recruitment
of other sequence-specific transcription factors that are believed to cooperate with CREB to
mediate calcium-specific gene expression. We focused on the calcium-regulated factor
MEF2 because ongoing studies in our lab have extensively validated the antibody directed
against MEF2D for use in ChIP (S.W.F, T.K.K. and M.E.G., manuscript in preparation).
Using this antibody, we observed strong binding of MEF2D to Bdnf promoter IV in loxP
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control brains that is significantly reduced in CREmKI littermate brains (Figure 8E). In
contrast, we detected enrichment of the Nr4a1 promoter, a well-characterized target of
MEF2 transcriptional regulation, in anti-MEF2D immunoprecipitates from both CREmKI
and loxP control brains (Figure 8E), and little MEF2D binding to negative control regions in
the Bdnf and Nr4a1 genes in either CREmKI or loxP control brains (Figure 8E and data not
shown). Thus, the loss of CREB binding to Bdnf promoter IV disrupts the binding of
MEF2D to Bdnf promoter IV as well. Our failure to observe the binding of many
components of the transcriptional activating complex — CBP, polII, and MEF2D — to Bdnf
promoter IV in CREmKI brains does not reflect a general inability to immunoprecipitate
promoter IV-containing gDNA fragments from CREmKI brains because promoter IV
fragments are found to be equally enriched in CREmKI and loxP control chromatin
immunoprecipitates collected with an antibody that recognizes histone H3, a core structural
component of chromatin (Figure 8F). Taken together, our findings indicate that loss of
CREB binding to Bdnf promoter IV disrupts the multi-factor transcriptional activating
complex at promoter IV and suggest a new function for CREB in nucleating the assembly of
transcriptional complexes at its target promoters.
DISCUSSION
Despite more than two decades of investigation into the program of gene expression that is
regulated by neuronal activity in the brain, a significant gap persists in our understanding of
the biological significance of the activity-dependent component of gene transcription. In this
study, the introduction of a subtle mutation into the endogenous Bdnf gene in mice to disrupt
the ability of CREB to bind Bdnf promoter IV represents a powerful approach for selectively
evaluating the functional significance of activity-dependent Bdnf transcription. We show
that disruption of the ability of CREB to regulate Bdnf promoter IV results in an animal in
which the activity-dependent transcription of Bdnf is impaired in response to sensory
experience-driven synaptic activation in the intact brain. Using this animal, we find that
activity-dependent Bdnf expression is required for the appropriate development of inhibition
in the cortex, but does not appear to affect the survival or differentiation of GABAergic
neurons. These results demonstrate the biological importance of activity-regulated gene
transcription for the establishment of appropriate connectivity in the nervous system. In
addition, our findings also indicate a requirement for promoter IV-derived Bdnf in the
development of inhibition in the cortex and thus provide insight into the functional
significance of the complex, multi-promoter organization of the Bdnf gene.
Most previous studies examining the role of activity-regulated gene transcription in the
nervous system have taken the approach of disrupting either genes whose transcription, or
transcription factors whose function, is regulated by neuronal activity. For example, the
observation of defects in synaptic plasticity and learning in hypomorphic mutants of the
transcription factor CREB (Balschun et al., 2003; Bourtchuladze et al., 1994; Gass et al.,
1998) has been taken as evidence of the importance of neuronal activity-dependent
transcription in these adaptive processes, since CREB is a well-established regulator of
calcium-dependent gene expression. Experiments with this design, however, cannot easily
dissociate the functions of a gene that are due specifically to its regulation by neuronal
activity from the many other influences on its action. In the case of CREB, for instance,
interpretation of its role in synaptic and behavioral plasticity is complicated by its essential
role in neuronal survival and maintenance (Mantamadiotis et al., 2002; Rudolph et al.,
1998). The current study is distinguished by our ability to make use of the substantial
existing mechanistic understanding of Bdnf transcription to specifically disrupt neuronal
activity-dependent Bdnf transcription in vivo, via the genetic mutation of the CREB-binding
site in Bdnf promoter IV. This objective can be achieved because, although CREB can be
activated by multiple signaling pathways including those mediated by rises in cyclic AMP,
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exon IV-containing Bdnf transcripts are induced selectively in response to the influx of
extracellular calcium. Furthermore, since promoter IV-derived Bdnf transcripts comprise the
majority of activity-induced Bdnf transcripts expressed in the cortex, the disruption of
activity-regulated promoter IV activity results in a substantial impairment in overall
neuronal activity-dependent Bdnf transcription in the cortex.
Several phenotypic aspects of the CREmKI mutant animal also suggest that the changes in
the development and function of its nervous system specifically reflect defects in the
neuronal activity-regulated expression of Bdnf. For instance, in contrast to total Bdnf−/−
knockout mice which typically die in the first few days of life (Ernfors et al., 1994; Jones et
al., 1994), CREmKI mutants are viable, fertile, and appear indistinguishable from control
littermates. In addition, at a gross anatomical level CREmKI brains do not appear
significantly different from wildtype or loxP control littermate brains (Supplemental Figure
4A), and cortical layering in CREmKI brains appears normal (Supplemental Figure 4B),
suggesting that impairment of activity-dependent promoter IV expression does not have
strong effects on neuronal survival. Furthermore, whereas total Bdnf−/− null animals have a
dramatic reduction in the number of inhibitory neurons in the cortex (Jones et al., 1994), we
do not observe a change in inhibitory neuron number in CREmKI cortex (Figure 7E–F),
again indicating that not all Bdnf-dependent phenotypes are affected by deficits in activity-
dependent promoter IV activation. Like in Bdnf+/− heterozygous mutants, the level of
cortical BDNF protein in CREmKI animals reared in standard housing conditions is
approximately 50% of controls (Supplemental Figure 3), and, like CREmKI animals,
Bdnf+/− heterozygotes also exhibit deficits in the development of inhibition in the visual
cortex (Abidin et al., 2008). However, a simple 50% reduction in BDNF protein level cannot
account for the phenotype of the CREmKI animal because, unlike Bdnf+/− heterozygous
mutants that develop obesity by three months of age (Kernie et al., 2000; Lyons et al., 1999),
preliminary evaluation suggests that CREmKI mutants do not exhibit changes in body
weight regulation (Supplemental Figure 7). Taken together, these observations are consistent
with the idea that the defects in cortical inhibition seen in the CREmKI mutant reflect a
requirement for Bdnf function that depends specifically on the activity-dependent expression
of the gene. It is important to note that, since activity-dependent Bdnf expression is
significantly attenuated, but not completely eliminated in the CREmKI animal, we cannot
exclude the possibility that many of the well-characterized phenotypes of Bdnf−/− and
Bdnf+/− mice that are not apparent in the CREmKI animal may ultimately prove to also be
dependent on activity-dependent Bdnf transcription.
The finding that activity-dependent Bdnf expression is important for the development of
GABAergic synapses in the visual cortex indicates an important role for activity-regulated
gene transcription in the control of cortical excitability. The establishment and maintenance
of appropriate excitatory-inhibitory balance is critical to normal brain physiology and
function; defects in excitatory-inhibitory balance can lead to the emergence of seizures and
aberrant critical periods for cortical plasticity (Hensch and Fagiolini, 2005; Sun, 2007).
Previous studies have demonstrated that a reduction in excitatory drive caused by sensory
deprivation leads to a decrease in GABA immunoreactivity in the visual cortex (Benevento
et al., 1995; Hendry and Jones, 1986), suggesting the hypothesis that the level of neuronal
activity can adjust the strength of cortical inhibition to maintain appropriate firing rates in
cortical circuits. Since BDNF levels can serve as a molecular “sensor” of global levels of
neuronal activity, it has been suggested that the induction of Bdnf expression in response to
increases in the level of neuronal activity may act to dampen cortical excitability by
promoting the development and/or strengthening of inhibitory synapses in local circuits
(Genoud et al., 2004; Rutherford et al., 1997). However, direct evidence that the neuronal
activity-dependent regulation of Bdnf expression controls the level of excitability of cortical
circuits has been lacking. Our finding that the disruption of neuronal activity-regulated Bdnf
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expression impairs the development of inhibitory synapses provides strong evidence in
support of this hypothesis. Since levels of Bdnf no longer function as an accurate sensor of
neuronal activity in CREmKI brains, cortical circuits appear to form as if under conditions
of chronic sensory activity deprivation and fail to develop the appropriate level of inhibition.
Important future experiments include pinpointing the source(s) of activity-dependent BDNF
expression and release, the cellular target(s) on which it acts, and understanding whether
activity-regulated BDNF functions equivalently at all inhibitory inputs or may have local
effects near specific or active synapses.
In addition to demonstrating the biological significance of activity-regulated Bdnf
transcription for brain development and function, our findings provide new insight into the
action of CREB in the nervous system. We show that loss of the ability of CREB to bind and
regulate Bdnf promoter IV in CREmKI brains results in defects in the development of
cortical inhibition, implicating CREB, or possibly its closely related family members CREM
and ATF-1, as having a previously unappreciated function in the development of inhibition
in the nervous system. Our results with the CREmKI animal demonstrate that assessing the
function of transcriptional regulators via the mutation of their binding sites in their target
promoters is a powerful approach that can deconvolve the many functions of the factor
(Xiang et al., 2006). Additionally, in the case of a transcriptional regulator like CREB that
belongs to a multi-factor family, the approach of mutating the factor binding site in target
promoters of interest avoids a potential complication of gene knockout studies, in which
compensation of one family member for another’s function is common.
Our results also provide insight into the role of CREB in the formation of transcriptional
regulatory complexes at gene promoters. We find that loss of CREB binding in CREmKI
brains results in disruption of core components of the transcriptional activating complex at
Bdnf promoter IV, including CBP and PolII, as well as loss of another sequence-specific
transcription factor MEF2 that cooperates with CREB to regulate promoter IV activity
(S.W.F., T.K.K., and M.E.G, manuscript in preparation). These results suggest a central
function for CREB in nucleating the assembly of the multi-factor transcriptional regulatory
complex that mediates calcium-dependent exon IV transcription. This idea is supported by
our observation that additional mutation of the CaRE1 and CaRE2 sites in addition to the
CaRE3/CRE site does not impair activity-dependent promoter IV induction significantly
more than mutation of the CREB-binding site alone. Although there is evidence that CREB,
both directly and through its association with CBP, can bind and stabilize components of the
pre-initiation complex (Lonze and Ginty, 2002), whether CREB recruits other sequence-
specific transcriptional activators to its target promoters was less clear. One possibility is
that the co-activator CBP has additional functions as a molecular scaffold to bridge the
interactions among the many factors in a transcriptional complex, such that recruitment of
CBP by activated CREB leads to the stabilization of additional sequence-specific factors at
the promoter. Alternatively, CREB may interact directly with other sequence-specific
factors to recruit them to promoter IV, as has recently been shown for the transcriptional
regulator MeCP2 (Chahrour et al., 2008). Further characterization of the multi-factor
transcriptional complex, as well as putative changes in chromatin state, at Bdnf promoter IV
in CREmKI neurons may yield new insight into the general mechanisms by which CREB
coordinates the stimulus-specific activation of its target promoters.
Taken together, our results demonstrate that the neuronal activity-dependent component of
gene expression is an important functional mediator of the effects of neuronal activity in
reorganizing synaptic connectivity in the nervous system. It is remarkable that the
impairment in the ability of neuronal activity to trigger the expression of just one of eight
promoters of a single gene, Bdnf, results in significant defects in the development of cortical
inhibition, highlighting the importance of the exquisite level of transcriptional control over
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Bdnf expression in the nervous system. Our finding that activity-regulated Bdnf expression is
an important mediator of the effect of neuronal activity on the development of cortical
inhibition suggests that, more generally, a major function of the program of neuronal
activity-regulated gene expression may be to regulate the level of excitability of cortical
circuits. Aberrant excitatory-inhibitory balance in the cortex can have significant
consequences for the nervous system, including the development of seizures and abnormal
critical periods for cortical plasticity, two common features of mental retardation,
neurodevelopmental and autism spectrum disorders (Hensch and Fagiolini, 2005;
Rubenstein and Merzenich, 2003). These observations highlight the importance of continued
investigation into the full program of neuronal activity-regulated genes, and the synapse-to-
nucleus signaling pathways that regulate their expression, for understanding how experience
shapes the nervous system and how defects in this process may lead to disorders of
cognition.
METHODS
See Supplemental Methods for details of animal husbandry and colony management,
neuronal cell culture, immunocytochemistry, immunohistochemistry, image analysis, and
electrophysiology
Generation of Bdnf pIV−/−, TMKI, CREmKI, and loxP control mice
See Supplemental Methods for description of gene targeting. The Bdnf pIV deletion spans
basepairs −160 to +281 relative to the TSS. All experiments were performed with animals in
a sv129/C57BL/6 mixed genetic background, with the mutation backcrossed into the
C57BL/6 background between four and six generations.
Visual stimulation and seizure induction
Eight- to twelve-week old adult mice reared in a 12-hour:12-hour light:dark cycle were
transferred into constant darkness for 14 days. Animals in the stimulated (+) condition were
exposed to light for 90 minutes. Seizures were induced in 8–12 week old adult mice by
intraperitoneal injection of kainic acid (20 mg/kg). At the indicated times post-injection,
mice were killed and the cortex isolated. See Supplemental Methods for details.
Gene expression analysis
cDNA was synthesized by reverse transcription of total RNA using oligo-dT priming, and
transcript levels were measured by quantitative real-time PCR using SYBR Green detection.
BDNF protein levels were quantified by two-site ELISA. See Supplemental Methods for
details.
Chromatin immunoprecipitation
For anti-CREB or anti-MEF2D ChIP, the antibody was pre-incubated with either the antigen
peptide against which the antibody was raised (negative control IP) or an irrelevant peptide
(experimental IP) prior to use in immunoprecipitation. For all other factors, normal mouse or
rabbit IgG was used for the negative control IP. See Supplemental Methods for details.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Generation of Bdnf pIV, TMKI, CREmKI, and loxP control mice. A) Genomic structure of
the rodent Bdnf gene adopted from Aid et al., 2007. The discovery of additional exons in the
rodent Bdnf gene has resulted in changes in exon nomenclature; the four major transcripts
now known as I, II, IV, and VI were initially described as I, II, III, and IV (in red),
respectively, in Timmusk et al., 1993. B) Targeting strategy for the introduction of pIV,
TMKI, CREmKI, and loxP control mutations into Bdnf promoter IV by homologous
recombination. P, PciI; A, AgeI; S, SphI; 5’, 3’ Southern probes; NEO/ZEO, neomycin-
zeomycin positive selection cassette; DTA, diphtheria toxin negative selection cassette. C)
Southern blot analysis of PciI-digested genomic DNA from targeted ES cells using the 5’
probe indicates correct targeting of each mutation. pIV: WT, 11.6 kb; mut., 5.3 kb; TMKI,
CREmKI, loxP control: WT, 11.6 kb; mut., 5.7 kb. D) Direct sequencing of PCR products
amplified from genomic DNA isolated from TMKI, CREmKI, or loxP control homozygous
mice using primers spanning Bdnf promoter IV.
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Figure 2.
Activity-dependent Bdnf transcription in pIV−/−, TMKI, and CREmKI cortical neurons is
impaired in response to membrane depolarization. Levels of Bdnf exon IV (A–C), exon IX
(coding exon) (D–F), and c-fos (G–I) mRNA in 5DIV cortical neurons prepared from
pIV−/− and wildtype littermates (A,D,G), homozygous TMKI and loxP control littermates
(B,E,H), or homozygous CREmKI and loxP control littermates (C,F,I) that were either left
untreated or membrane depolarized with high extracellular potassium for the indicated
amounts of time. Differences in Bdnf exon IV and total Bdnf mRNA expression are
statistically significant for pIV−/−, TMKI, or CREmKI versus their respective controls
(P<0.01, repeated-measures ANOVA; P<0.01, pairwise comparisons at each timepoint 1 hr
or longer, Bonferroni-Dunn post-hoc test). Data are mean ± SEM from n=3 (pIV−/− and
CREmKI) or n=2 (TMKI) independent experiments in which each sample was measured in
triplicate.
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Figure 3.
Neuronal activity-dependent Bdnf transcription in CREmKI cortical neurons is impaired in
response to glutamate receptor activation. Levels of Bdnf exon IV (A), total Bdnf (exon IX)
(B), Bdnf exon I (C), Bdnf exon II (D), NP2 (E), and Bdnf exon VI (F) mRNA in 12DIV
cortical neurons prepared from CREmKI or loxP control littermates that were either mock-
stimulated or treated with 20µM NMDA for the indicated amounts of time. Asterisk denotes
P<0.01, repeated-measures ANOVA, pairwise comparisons at indicated timepoints,
Bonferroni-Dunn post-hoc correction. Data are mean ± SEM from n=2 independent
experiments in which each sample was measured in triplicate.
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Figure 4.
Sensory experience-dependent Bdnf expression is impaired in the intact CREmKI brain. A–
B) Levels of the indicated transcripts in the primary visual cortex of adult CREmKI and
loxP control mice reared in darkness for 14 days, after which they were either maintained in
darkness (−) or exposed to light for 90 min. (+). Within each transcript, mRNA levels are
reported as fold induction relative to the loxP control unstimulated (−) condition. In either
loxP control or CREmKI visual cortex, light stimulation induced the expression of all
mRNAs measured (P<0.01, two-way ANOVA with Bonferroni Dunn post-hoc test), except
for gapdh, which served as a non-activity-regulated gene control. C–E) Bdnf exon IV, total
Bdnf, and c-fos mRNA levels in the cortex of CREmKI and loxP control mice injected with
either saline (time 0) or kainic acid (KA) for the indicated amounts of time. F) Levels of
BDNF protein in the primary visual cortex of animals from A–B. G) The unstimulated (−)
levels of Bdnf exon IV and total Bdnf in CREmKI and loxP control visual cortex are re-
plotted from A) for direct comparison (P>0.05, two-way ANOVA with Bonferroni-Dunn
post-hoc test). Data are from n=5–7 animals per condition for both visual stimulation and
KA seizure experiments. Each animal was measured in triplicate, and data are presented as
mean ± SEM. Asterisks denote P<0.01, two-way (visual simulation) or repeated-measures
(KA seizure) ANOVA with Bonferroni-Dunn post-hoc test between indicated pair.
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Figure 5.
Impaired activity-dependent Bdnf expression reduces the number of inhibitory synapses
formed on CREmKI neurons in culture. A) Representative images of GFP-transfected,
E17.5 + 18DIV CREmKI and loxP control littermate cortical neurons, immunostained with
the indicated antibodies to label pre- and post-synaptic inhibitory synapse terminals. Scale
bar, 10µm. B) Enlargement of the boxed area in A shows details of dendrites. The GFP
signal is converted to gray to allow better visualization of the synaptic puncta. Scale bar,
5µm. C–E) Quantification of the average density of GAD65/GABAARγ2 (C, 78–81 cells/
condition), VGAT/GABAARβ2/3 (D, 65–66 cells/condition), and synapsinI/PSD-95 (E, 63–
65 cells/condition) co-clusters along the dendrites of GFP-transfected CREmKI and loxP
control neurons. Asterisk denotes P<0.01, two-way ANOVA with pairwise comparison by
Bonferroni-Dunn post-hoc test. Data are mean±SEM from 3–4 independent experiments. F)
Quantification of dendritic branch complexity by Sholl analysis plots the number of
dendritic branches intersecting concentric circles of increasing radii centered on the cell
body. P>0.05 by repeated-measures ANOVA; data are mean±SEM from 26–28 cells/
condition from 2 independent experiments.
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Figure 6.
Neuronal activity-dependent Bdnf expression controls the development of cortical inhibition.
A) Representative traces of mIPSCs recorded from layer II/III V1 pyramidal neurons in loxP
control and CREmKI acute cortical slices. B) Cumulative probability distributions of mIPSC
interevent intervals (I) and amplitudes (II) recorded from loxP control and CREmKI
neurons. P<0.01 by either Kolmogorov-Smirnov test or Monte Carlo simulation (see
Supplemental Methods). C) Average interevent interval (I) and amplitude (II) of mIPSCs
recorded from loxP control and CREmKI neurons. Data are mean ± SEM, P<0.01 by
Student’s t-test. Data are from 18–20 cells/genotype recorded from 12 pairs of littermates.
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Figure 7.
Reduced immunoreactivity for inhibitory synaptic markers in CREmKI cortex. A)
Representative images of immunostaining with antibodies recognizing GAD65 (red), which
is enriched in inhibitory presynaptic terminals, and VGLUT1 (green), which is enriched at
excitatory presynaptic terminals, in layer II/III of CREmKI and loxP control primary visual
cortex. Scale bar, 5µm. B–D) Quantification of the average intensity of α-GAD65 (B, 74–77
fields/genotype), α-VGAT (C, 48 fields/genotype), and α-VGLUT1 (D, 48 fields/genotype)
immunostaining in CREmKI and loxP control littermates. Asterisk indicates P<0.01, two-
way ANOVA with pairwise comparison by Bonferroni-Dunn post-hoc test. Data are mean ±
SEM from 3–4 pairs of littermates. E–F) Quantification of the number of paralbumin- (E)
and NPY- (F) positive inhibitory neurons in the primary visual cortex of CREmKI and loxP
control littermates, normalized to the number of total nuclei. P>0.05 for either parvalbumin-
positive or NPY-positive neurons, two-way ANOVA. Data are mean ± SEM collected from
n=24 hemispheres from 3 pairs of littermates.
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Figure 8.
Loss of CREB binding at Bdnf promoter IV in CREmKI brains leads to the disassembly of
the transcriptional activating complex at Bdnf promoter IV. A) α-CREB immunoprecipitates
were isolated from the cross-linked forebrains of CREmKI and loxP control littermates
under conditions identical to those used for chromatin immunoprecipitation (ChIP) and
analyzed by Western blotting with an independent antibody against CREB. B–F) qPCR
measurement of the levels of the indicated genomic DNA regions in α-CREB (B), α-
CBP(C), α-polymerase II (D), α-MEF2D (E), and α-histone H3 (F) chromatin
immunoprecipitates prepared from the forebrains of CREmKI and loxP control littermates.
Asterisk denotes P<0.01, two-way ANOVA with pairwise comparison by Bonferroni-Dunn
post-hoc test. Data are mean ± SEM from n=4 (α-CREB), n=3 (α-MEF2D, α-CBP), or n=2
(α-pol II, α-H3) independent experiments in which each sample was measured in triplicate.
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